APR 19, 2020 3:35 PM PDT

FDA Approves New Drug for Breast Cancer

WRITTEN BY: Annie Lennon

 

The US Food and Drug Administration has approved a new drug, known as tucatinib or Tuksya, as a treatment for advanced forms of breast cancer. To be used alongside chemotherapy, it has been approved for cancer that cannot be removed by surgery, and that have spread to other parts of the body including the brain. 

In particular, the drug works against HER2-positive breast cancer- when the body has an excessive amount of a cancer-growing protein known as human epidermal growth factor receptor 2 (HER2). Responsible for around 1 in 5 cases of breast cancer, around 25% of women with the condition also develop brain metastases. 

The FDA approved Tuksya based on results from a controlled clinical trial examining its effects on 612 patients with treatment-resistant HER-2 positive breast cancer. In the end, the researchers found that patients who received the drug alongside chemotherapy and drugs trastuzumab and capecitabine had a progression-free survival (time in which the patient lives with the disease but it does not get worse) of 7.8 months compared to the 5.6 months of those on a placebo. Meanwhile, the overall survival and progression-free survival rate of those on the drug was 21.9 months as opposed to 17.4 months for those on the placebo. 

The researchers also noted that common side effects of the drug are diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, liver damage, decreased appetite and anemia among others. Meanwhile, they noted that serious side effects included severe diarrhea, acute kidney injury and death. 

"We recognize that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease," says Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence. "In this critical time, we remain steadfast in our commitment to patients with cancer and doing everything we can to expedite oncology product development. Tukysa was approved four months prior to the FDA goal date, providing an example of this commitment and showing how our regular work in reviewing treatments for patients with cancer is moving forward without delay."



Sources: FDA, CNN

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 21, 2022
Health & Medicine
Inhibiting a Key Signaling Pathway in Immune Cells Slows Alzheimer's Progression
APR 21, 2022
Inhibiting a Key Signaling Pathway in Immune Cells Slows Alzheimer's Progression
Weill Cornell Medicine researchers recently discovered that inhibiting a key signaling pathway in brain cells can lessen ...
APR 21, 2022
Clinical & Molecular DX
An Emerging Need to Diagnose Maladaptive Daydreaming
APR 21, 2022
An Emerging Need to Diagnose Maladaptive Daydreaming
Maladaptive daydreaming (MD), also called daydreaming disorder, occurs in people who experience intense daydreams o ...
MAY 17, 2022
Cancer
Looking for an Easier Way to Scale-up Your Benchtop Cell Cultures?
MAY 17, 2022
Looking for an Easier Way to Scale-up Your Benchtop Cell Cultures?
Much has been written about scaling up cell culture for bioprocessing and other applications that require a very high de ...
MAY 13, 2022
Drug Discovery & Development
Multiple Mental Health Diagnoses are Increasingly Common. Why?
MAY 13, 2022
Multiple Mental Health Diagnoses are Increasingly Common. Why?
Mental illness has become increasingly common. The number of people with anxiety and depression, specifically, has stead ...
MAY 19, 2022
Neuroscience
Daily Cranberry Consumption Boosts Cognitive Function, Reduces Cholesterol
MAY 19, 2022
Daily Cranberry Consumption Boosts Cognitive Function, Reduces Cholesterol
Eating a cup of cranberries per day may improve memory, ward off dementia and reduce ‘bad’ cholesterol in th ...
JUN 20, 2022
Health & Medicine
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
JUN 20, 2022
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
The New England Journal of Medicine published results from a small study by researchers at New York’s Memorial Slo ...
Loading Comments...